# Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

> **NCT04574856** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **RADIATION:** Dose-Intensified Radiotherapy
- **DRUG:** Temozolomide
- **DRUG:** Adjuvant temozolomide

## Key facts

- **NCT ID:** NCT04574856
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-04
- **Primary completion:** 2026-11-19
- **Final completion:** 2027-11-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04574856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04574856, "Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04574856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*